Core Insights - SafeSpace Global Corp. is attending the NIC Spring Conference 2026 to connect with senior living operators, healthcare executives, and investment leaders focused on safety and care outcomes [1][2] - The conference highlights emerging trends in health, personal care, and supportive services for older adults, emphasizing the integration of housing and healthcare services [3] Company Overview - SafeSpace Global Corporation is a publicly traded technology company that provides proprietary multimodal, advanced AI safety solutions aimed at saving lives [4] - The company's platform offers advanced threat detection, incident notification, and comprehensive security capabilities across various sectors [4] Financial Performance - As of February 2026, SafeSpace Global is generating recurring monthly revenue through service contracts with senior living facilities utilizing its AI-powered safety monitoring platform [5]

Financial Performance - United-Guardian, Inc. reported a 13% decrease in net sales for FY 2025, falling from $12,181,971 in 2024 to $10,545,468 in 2025 [1][5] - Net income also declined from $3,250,875 ($0.71 per share) in 2024 to $2,105,738 ($0.46 per share) in 2025 [1][6] Sales Breakdown - The decline in sales was primarily due to reduced sales of cosmetic ingredients, attributed to excess inventory held by the largest distributor, Ashland Specialty Ingredients, and decreased global demand, particularly in China [2] - Conversely, sales of pharmaceuticals increased by 15% and medical lubricants by 4% in 2025 compared to 2024, driven by higher demand from contract manufacturers in China and increased sales to national drug wholesalers [2] Strategic Initiatives - The company is implementing a new marketing strategy to expand domestic sales of Renacidin, which includes increasing awareness and seeking inclusion on additional drug formularies [2] - Recent approvals from two major pharmacy benefit managers are expected to enhance patient access and support long-term commercial growth for Renacidin [2] Financial Data - Total costs and expenses for 2025 were $8,302,120, down from $8,535,182 in 2024 [5][6] - The company's total assets decreased from $13,797,335 in 2024 to $13,108,579 in 2025, while stockholders' equity also fell from $11,882,866 to $11,232,012 [8]

Core Insights - Kartoon Studios is set to release its annual Shareholder Letter and Business Update on March 31, featuring a pioneering AI-animated video presentation that includes company executives and characters from the upcoming Hundred Acre Wood series [2][6] - The presentation aims to showcase the company's AI-powered animation production capabilities, which are expected to revolutionize the speed, cost structure, and creative potential of animated content production [3][6] Company Overview - Kartoon Studios (NYSE American: TOON) is a leading entity in children's and family entertainment, providing premium content and animated intellectual property to a global audience [7] - The company operates Mainframe Studios, one of North America's largest animation producers, with over 22,000 minutes of award-winning programming [7] Strategic Initiatives - The presentation will feature key executives, including Founder and CEO Andy Heyward, CFO Brian Parisi, and President of Toon Media Networks Todd Steinman, discussing the company's operational performance and strategic growth initiatives [4] - The company is strategically positioned for sustained growth, with a global distribution footprint in over 60 territories and a robust content pipeline [8]

Core Viewpoint - AnaptysBio, Inc. is proceeding with the spin-off of First Tracks Biotherapeutics, Inc., which has secured a $145 million private placement agreement with third-party investors, expected to close upon the completion of the spin-off on April 20, 2026 [1][2]. Group 1: Financial Details - First Tracks Bio is selling 5,791,478 shares at a price of $13.81 per share, generating $80 million in gross proceeds [2]. - The Selling Stockholder is selling 4,705,576 shares at the same price, contributing to the overall financing [3]. - The total cash available for First Tracks Bio at launch will be $180 million, including proceeds from the private placement, providing a two-year cash runway [8]. Group 2: Use of Proceeds - Proceeds from the sale of shares will be utilized for general corporate purposes, specifically for the clinical development of ANB033, a CD122 antagonist [3]. Group 3: Investor Participation - The financing round includes participation from various investors such as 683 Capital Partners, Adage Capital Partners, and others, with placement agents being Leerink Partners, Barclays, and UBS Investment Bank [4].

Core Viewpoint - Jeffs' Brands Ltd is expanding into the global homeland security sector through its subsidiary KeepZone AI Inc, which has entered into a non-exclusive Agent Agreement with Skyline Software Systems to market and distribute advanced 3D geospatial visualization solutions [1][2][5] Group 1: Agreement Details - KeepZone is authorized to market, sell, and distribute Skyline's proprietary 3D GIS and photogrammetry solutions, including TerraExplorer, PhotoMesh, and SkylineGlobe, in designated territories in the Middle East, Europe, and Latin America [2] - The collaboration enhances KeepZone's existing AI-powered security solutions, providing a comprehensive security ecosystem with real-time 3D intelligence capabilities [4] Group 2: Strategic Importance - The addition of Skyline's technology is seen as a significant advancement in KeepZone's mission to deliver integrated AI-driven security solutions for defense and critical infrastructure [5] - This Agreement is part of KeepZone's broader strategy to expand its homeland security product portfolio through collaborations with leading technology providers [5][6] Group 3: Company Background - Jeffs' Brands is a data-driven e-commerce company that has recently pivoted into the homeland security sector, aiming to leverage its expertise in data-driven operations to capitalize on the market's growth potential [6]

To Nasdaq Copenhagen Announcement of drawings (CK95) Pursuant to s 24 Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes drawings data as at 25 March 2026. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be ad ...

Key Information - Rathbones Group Plc disclosed a position in relevant securities representing 1% or more, specifically in a consortium involving LondonMetric Property plc and Schroder Real Estate Investment Trust Limited [1] - The position was held as of March 26, 2026, and the disclosure was made on March 27, 2026 [1][15] Positions of the Discloser - Rathbones Group Plc holds 85,598,860 ordinary shares in LondonMetric Property plc, representing 3.65% of the total [3] - Additionally, it holds 19,902,493 ordinary shares in Schroder Real Estate Investment Trust Limited, representing 4.06% of the total [4] Dealings - Rathbones Group Plc engaged in multiple transactions involving LondonMetric 10p Ordinary Shares, including sales and purchases at various prices, with the highest purchase price being 181.084p and the lowest sale price being 178.657p [7] - For Schroder REIT Ordinary NPV Shares, sales were made at prices ranging from 46.376224p to 46.9816p [8]

Core Viewpoint - VERSES AI Inc. has successfully completed a second tranche of its non-brokered private placement, raising a total of C$1,100,930 (approximately US$797,717) to strengthen its financial position and support ongoing operations [1][3]. Group 1: Offering Details - The second tranche involved the issuance of 473,500 units at a price of C$0.75 (US$0.54) per unit, generating gross proceeds of C$355,125 (approximately US$257,318) [1]. - The total offering consists of 1,644,307 units, which includes the previously completed tranche announced on March 16, 2026 [1]. - Each unit comprises one Class A Subordinate Voting Share and one-half of a Share purchase warrant, with each warrant allowing the purchase of one share at an exercise price of C$1.00 (approximately US$0.72) [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to enhance the company's financial stability and provide liquidity for ongoing operations, particularly for research and development expenses, working capital, and general corporate purposes [3]. Group 3: Finder's Fees and Warrants - In connection with the second tranche, the company paid cash finders' fees of C$10,410 (approximately US$7,543) and issued 29,880 finder warrants to assist with the offering [4]. - Each finder warrant allows the holder to acquire one finder unit at a price of C$0.75 (approximately US$0.54) for a period of 24 months, with each finder unit consisting of one share and one-half of a share purchase warrant [4]. Group 4: Securities Regulations - All securities issued under the offering are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with Canadian securities legislation [5]. - The units and underlying shares and warrants have not been registered under the U.S. Securities Act and cannot be offered or sold in the United States without proper registration or exemption [6].

Core Insights - Callan JMB Inc. is collaborating with DifGen Pharmaceuticals and Aveva Drug Delivery Systems to support the U.S.-based technology transfer and manufacturing scale-up for the JKB-122 (Lodonal) immune restoration platform [1][6] Group 1: Company Role and Responsibilities - Callan JMB's role includes independent validation across manufacturing, quality systems, and supply chain operations to ensure compliance and readiness for Phase 2b/3 clinical development [2][4] - The company provides oversight in manufacturing, storage, monitoring, packaging, and distribution, ensuring programs are scalable and ready for deployment in clinical and government settings [5][6] Group 2: Collaboration and Development - The collaboration aims to establish a unified CMC framework for multi-indication development, with a focus on programs addressing Post-Acute Sequelae of SARS-CoV-2 Infection, Autoimmune Hepatitis, and other conditions [5][6] - DifGen Pharmaceuticals and Aveva Drug Delivery Systems are leading formulation development and manufacturing expansion, supporting various dosage forms and stability optimization [7][11] Group 3: Industry Context and Trends - The initiative reflects a broader industry trend towards platform-based therapeutic development and integrated manufacturing strategies to support multiple indications [8] - Callan JMB's expertise in logistics and operational infrastructure is critical for regulated healthcare programs requiring compliance and operational integrity [9]

Core Viewpoint - Axe Compute is set to release its financial results for the fiscal year ended December 31, 2025, and file its Annual Report on Form 10-K on March 31, 2026, reflecting its progress in AI compute infrastructure [1] Financial Results Announcement - The financial results will be released after market close on March 31, 2026 [1] - A conference call and webcast will be held on April 1, 2026, at 8:30 a.m. Eastern Time to discuss the results and business outlook [2] Conference Call Details - The conference call will include a dial-in option and a webcast registration link for investors [3] - A replay of the webcast will be available on the company's investor relations website [4] Company Overview - Axe Compute is focused on redefining AI compute infrastructure, providing enterprises and entrepreneurs with a globally distributed network across more than 200 locations [5] - The platform enables enterprise-grade AI compute deployments in as little as 48 hours without data egress or bandwidth charges, aiming to prevent vendor lock-in [5] - Axe Compute is one of the first publicly traded companies in the U.S. dedicated to building globally distributed AI compute infrastructure [5]